medric medric
[닫기]
잠시만 기다려 주세요. 로딩중입니다.

Effect of Ambrisentan Therapy on the Expression of Endothelin Receptor, Endothelial Nitric Oxide Synthase and NADPH Oxidase 4 in Monocrotaline-induced Pulmonary Arterial Hypertension Rat Model

Korean Circulation Journal 2019년 49권 9호 p.866 ~ 876
 ( Lee Hye-Ryon ) - Ewha Womans University School of Medicine Department of Pediatrics

 ( Yeom A-Rim ) - Ewha Womans University School of Medicine Department of Pediatrics
 ( Kim Kwan-Chang ) - Ewha Womans University School of Medicine Department of Thoracic and Cardiovascular Surgery
 ( Hong Young-Mi ) - Ewha Womans University School of Medicine Department of Pediatrics

Abstract


Background and Objectives: Elevated endothelin (ET)-1 level is strongly correlated with the pathogenesis of pulmonary arterial hypertension (PAH). Expression level of nicotinamide adenine dinucleotide phosphate oxidase (NOX) 4 is increased in the PAH patients. Ambrisentan, a selective endothelin receptor A (ERA) antagonist, is widely used in PAH therapy. The current study was undertaken to evaluate the effects of ambrisentan treatment in the monocrotaline (MCT)-induced PAH rat model.

Methods: Rats were categorized into control group (C), monocrotaline group (M) and ambrisentan group (Am). The M and Am were subcutaneously injected 60 mg/kg MCT at day 0, and in Am, ambrisentan was orally administered the day after MCT injection for 4 weeks. The right ventricle (RV) pressure was measured and pathological changes of the lung tissues were observed by Victoria blue staining. Protein expressions of ET-1, ERA, endothelial nitric oxide synthase (eNOS) and NOX4 were confirmed by western blot analysis.

Results: Ambrisentan treatment resulted in a recovery of the body weight and RV/left ventricle+septum at week 4. The RV pressure was lowered at weeks 2 and 4 after ambrisentan administration. Medial wall thickening of pulmonary arterioles and the number of intra-acinar arteries were also attenuated by ambrisentan at week 4. Protein expression levels of ET-1 and eNOS were recovered at weeks 2 and 4, and ERA levels recovered at week 4.

Conclusions: Ambrisentan administration resulted in the recovery of ET-1, ERA and eNOS protein expression levels in the PAH model. However, the expression level of NOX4 remained unaffected after ambrisentan treatment.

키워드

Hypertension, pulmonary; Endothelin receptor antagonists; Monocrotaline; Gene expression
원문 및 링크아웃 정보
  
등재저널 정보
SCI(E)
KCI
KoreaMed
KAMS